MarketPulse
A

$AIM

4 articles found
1 positive
1 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Flags Going Concern Despite Clinical Trial Progress

AIM ImmunoTech disclosed going concern warnings in 2025 audited statements but expressed confidence in fundraising backed by promising Ampligen-Imfinzi trial results.
AZNAIMPhase 2 clinical trialfundraising
BenzingaBenzinga··Nabaparna Bhattacharya

AIM ImmunoTech Surges 73% on Japanese Patent Victory for Cancer Therapy

AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.
AIMintellectual propertyorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Closes $1.8M Rights Offering to Fund Pancreatic Cancer Drug

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.
AIMclinical trialswarrants
BenzingaBenzinga··Globe Newswire

AIM ImmunoTech Raises $1.8M Through Rights Offering as Biotech Seeks Capital

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.
AIMwarrantscapital raise